Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Merck, Schering to combine blockbusters
Why not build on success? Schering-Plough and Merck are asking the FDA to approve a pill that combines the active ingredients of Singulair, the blockbuster asthma-and-allergy remedy, and Claritin, another best-selling allergy drug that went generic and over-the-counter in 2002. Under development by a joint venture of the two companies, the new product has been accepted for the FDA's standard review process.
- see the release on the combination package
Related Articles:
Drug combos not a sure thing. Report
New combos of old drugs may be boon to biotech. Report
New combo cholesterol drug being planned. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
